<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04731272</url>
  </required_header>
  <id_info>
    <org_study_id>848357</org_study_id>
    <nct_id>NCT04731272</nct_id>
  </id_info>
  <brief_title>GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance</brief_title>
  <official_title>Effect of GLP-1 Agonist Therapy on Insulin Secretion in Adults With Pancreatic Insufficient Cystic Fibrosis and Abnormal Glucose Tolerance: a Randomized, Open-label, Cross-over Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetes is a major co-morbidity in pancreatic insufficient cystic fibrosis (PI-CF) and&#xD;
      associated with worse outcomes. While reduced β-cell mass contributes to the insulin&#xD;
      secretory defects that characterizes cystic fibrosis-related diabetes (CFRD), other&#xD;
      modifiable determinants appear operative in the emergence and progression of abnormal glucose&#xD;
      tolerance towards diabetes. Identifying interventions to preserve β-cell function are crucial&#xD;
      for delaying and potentially preventing CFRD development. In this study, we hypothesize that&#xD;
      weekly administration of the long-acting glucagon-like peptide-1 (GLP-1) agonist dulaglutide&#xD;
      will improve defective early-phase insulin secretion and improve glucose tolerance during a&#xD;
      mixed-meal tolerance test.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 20, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2027</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2026</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Early-phase insulin secretion</measure>
    <time_frame>18 weeks</time_frame>
    <description>The primary outcome measure is the insulin secretory rate during the first 30-min during a mixed meal tolerance test (ISR-AUC30).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Early-phase insulin secretion adjusted for glucose excursion</measure>
    <time_frame>18 weeks</time_frame>
    <description>This secondary outcome measure is insulin secretory rate/glucose area under cure during the first 30-min during a mixed meal tolerance test (ISR-AUC30/ Glc-AUC30)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose tolerance</measure>
    <time_frame>18 weeks</time_frame>
    <description>This secondary outcome measure is mixed meal tolerance test-related glucose area under the curve over 180 min (Glc-AUC180).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Cystic Fibrosis</condition>
  <condition>Pancreatic Insufficiency</condition>
  <condition>Abnormal Glucose Tolerance</condition>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Dulaglutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Mixed Meal Tolerance Test as described in the primary outcome section will be performed at baseline and after 6 weeks of dulaglutide therapy in the intervention period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The Mixed Meal Tolerance Test as described in the primary outcome section will be performed at baseline and after 6 weeks of no intervention in the observation period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dulaglutide 0.75Mg/0.5Ml Inj Pen</intervention_name>
    <description>Randomized, open-label, cross-over study of 6 weeks exposure to dulaglutide 0.75 mg subcutaneous weekly or observation.</description>
    <arm_group_label>Dulaglutide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Male or female, aged ≥18 years on date of consent&#xD;
&#xD;
          -  2. Confirmed diagnosis of CF, defined by positive sweat test or Cystic Fibrosis&#xD;
             transmembrane conductance regulator (CFTR) mutation analysis according to Cystic&#xD;
             Fibrosis Foundation (CFF) diagnostic criteria.&#xD;
&#xD;
          -  3. Pancreatic insufficiency defined by clinical requirement for pancreatic enzyme&#xD;
             replacement.&#xD;
&#xD;
          -  4. Abnormal glucose tolerance defined by oral glucose tolerance test (OGTT) criteria&#xD;
             for early glucose intolerance (EGI), impaired glucose tolerance (IGT), or CFRD without&#xD;
             fasting hyperglycemia (fasting hyperglycemia is defined as fasting glucose ≥126 mg/dL)&#xD;
&#xD;
          -  5. Ability to take subcutaneous medication and be willing to adhere to the weekly&#xD;
             administration regimen and complete study specific procedures (MMTT)&#xD;
&#xD;
          -  6. For females of reproductive potential: use of highly effective contraception for at&#xD;
             least 1 month prior to screening and agreement to use such a method during study&#xD;
             participation and for an additional 6 weeks after the end of dulaglutide or&#xD;
             observation administration; oral contraceptives, intra-uterine devices, Norplant®,&#xD;
             Depo-Provera®, and barrier devices with spermicide are acceptable contraceptive&#xD;
             methods; condoms used alone are not acceptable&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. BMI &lt;19 kg/m2&#xD;
&#xD;
          -  2. Presence of first-degree atrioventricular block or other evidence for cardiac&#xD;
             conduction system or structural heart defects&#xD;
&#xD;
          -  3. Pregnancy or lactation; a negative urine pregnancy test will be required at&#xD;
             enrollment&#xD;
&#xD;
          -  4. Known allergic reactions to any GLP-1 agonist, and any history of severe&#xD;
             hypersensitivity reactions (anaphylaxis or angioedema)&#xD;
&#xD;
          -  5. Personal or family history of medullary thyroid cancer or multiple endocrine&#xD;
             neoplasia syndrome type 2 (MEN2)&#xD;
&#xD;
          -  6. Pulmonary exacerbation requiring IV antibiotics or systemic glucocorticoids within&#xD;
             4 weeks prior to study procedures&#xD;
&#xD;
          -  7. Gastrointestinal symptom exacerbation defined by current nausea/vomiting or&#xD;
             diarrhea&#xD;
&#xD;
          -  8. Established diagnosis of non-CF diabetes (e.g. type 1 diabetes) or CFRD with&#xD;
             fasting hyperglycemia (fasting glucose ≥126 mg/dL [use of prandial insulin or&#xD;
             repaglinide will be permitted])&#xD;
&#xD;
          -  9. History of clinically symptomatic pancreatitis within the last year&#xD;
&#xD;
          -  10. Prior lung, liver or other solid organ transplant&#xD;
&#xD;
          -  11. Severe CF liver disease, as defined by the presence of portal hypertension&#xD;
&#xD;
          -  12. History of fundoplication-related dumping syndrome&#xD;
&#xD;
          -  13. Hemoglobin &lt;10 g/dL, within 90 days of study procedures or at screening&#xD;
&#xD;
          -  14. Abnormal renal function, within 90 days of study procedures or at screening;&#xD;
             defined as creatinine &gt;2x upper limit of normal (ULN) or potassium &gt;5.5mEq/L on&#xD;
             non-hemolyzed specimen&#xD;
&#xD;
          -  15. History of any illness or condition that, in the opinion of the investigator might&#xD;
             confound the results of the study or pose an additional risk to the subject&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael R Rickels, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrea Kelly, MD, MSCE</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Philadelphia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kathryn Gallagher</last_name>
    <phone>215-746-2081</phone>
    <email>Kathryn.Gallagher2@pennmedicine.upenn.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cornelia Dalton-Bakes</last_name>
    <phone>215-746-2085</phone>
    <email>corneliv@pennmedicine.upenn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathryn Gallagher</last_name>
      <phone>215-746-2081</phone>
      <email>Kathryn.Gallagher2@pennmedicine.upenn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Cornelia Dalton-Bakes</last_name>
      <phone>215-746-2085</phone>
      <email>corneliv@pennmedicine.upenn.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Rickels, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrea Kelly, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 26, 2021</study_first_submitted>
  <study_first_submitted_qc>January 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2021</study_first_posted>
  <last_update_submitted>May 17, 2021</last_update_submitted>
  <last_update_submitted_qc>May 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Michael R. Rickels, MD, MS</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Cystic Fibrosis Related Diabetes</keyword>
  <keyword>Glucose Intolerance</keyword>
  <keyword>Insulin Secretion</keyword>
  <keyword>Glucagon-Like Peptide-1 (GLP-1)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dulaglutide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Upon completion of enrollment.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

